What role for AHR activation in IL4I1-mediated immunosuppression ?

Area of Science:

• Immunology
• Cancer Biology
• Enzymology

Background:

• Interleukin-4 induced gene 1 (IL4I1) is an amino-acid catabolizing enzyme with emerging relevance as a cancer therapeutic target.
• IL4I1, secreted by antigen-presenting cells, inhibits T cell receptor (TCR) signaling, influences T cell differentiation, and limits T cell proliferation.
• Tumor-expressed IL4I1 contributes to immune evasion by shaping the tumor microenvironment and impairing anti-tumor cytotoxic T cell responses.

Purpose of the Study:

• To investigate the proposed mechanism of IL4I1-mediated cancer immune suppression involving aryl-hydrocarbon receptor (AHR) activation.
• To clarify the role of IL4I1 in regulating T cell responses within the tumor microenvironment.

Main Methods:

• Analysis of IL4I1 expression correlation with AHR target genes in human cancers.
• Assessment of AHR target gene upregulation in dendritic cells in relation to IL4I1 expression in vivo.
• Evaluation of IL4I1's enzymatic activity on tryptophan and its potential to produce AHR-activating products, considering competition with other enzymes.

Main Results:

• IL4I1 expression showed poor correlation with validated AHR target genes in human cancers.
• Dendritic cells did not upregulate AHR target genes in response to IL4I1 expression in vivo.
• IL4I1's enzymatic activity on tryptophan is low and likely negligible in the presence of higher-affinity enzymes, suggesting minimal AHR activation.

Conclusions:

• The proposed mechanism of IL4I1-mediated immune suppression via AHR activation is not supported by current data.
• IL4I1 may restrain tumor control by regulating the priming of tumor-specific CD8 T cells, independent of AHR activation.
• Further research is needed to fully elucidate the mechanisms by which IL4I1 influences anti-tumor immunity.